Sabatine, Marc S.
Marc S Sabatine researcher
Sabatine, Marc S., 19..-....
VIAF ID: 48564878 (Personal)
Permalink: http://viaf.org/viaf/48564878
Preferred Forms
-
100 0 _ ‡a Marc S Sabatine ‡c researcher
-
-
100 1 _ ‡a Sabatine, Marc S
-
100 1 _ ‡a Sabatine, Marc S.
-
-
-
-
-
100 1 _ ‡a Sabatine, Marc S.
-
-
-
-
100 1 _ ‡a Sabatine, Marc S.
-
100 1 _ ‡a Sabatine, Marc S.
-
-
-
100 1 _ ‡a Sabatine, Marc S., ‡d 19..-....
4xx's: Alternate Name Forms (5)
Works
Title | Sources |
---|---|
Cardiovascular therapeutics : a companion to Braunwald's heart disease |
![]() ![]() |
Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Sy |
![]() |
Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes |
![]() |
The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics |
![]() |
Diagnostic and prognostic utility of brain natriuretic Peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema |
![]() |
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes |
![]() |
The Effect of PCSK9 Inhibition on the Risk of Venous Thromboembolism |
![]() |
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy |
![]() |
Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel |
![]() |
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizi |
![]() |
Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. |
![]() |
Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke |
![]() |
Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction |
![]() |
Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease |
![]() |
Frequency, Predictors and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients with Symptomatic Atherosclerosis. |
![]() |
Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials |
![]() |
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis |
![]() |
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. |
![]() |
Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group |
![]() |
Identification of patients at high risk for death and cardiac ischemic events after hospital discharge |
![]() |
Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial |
![]() |
Kieszonkowy podręcznik interny |
![]() ![]() |
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci |
![]() |
Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial |
![]() |
Medicina de bolso |
![]() |
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height |
![]() |
MGH naika shinryō manyuaru |
![]() |
MGH内科診療マニュアル |
![]() |
Minimal ST-segment deviation: a simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration |
![]() |
Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. |
![]() |
Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI ... |
![]() |
n99802628 |
![]() |
Naika poketto refaransu. |
![]() |
No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials |
![]() |
Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial |
![]() |
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials |
![]() |
Pharmcards : review cards for medical students |
![]() |
Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial |
![]() |
Pocket cardiology : a companion to Pocket medicine |
![]() ![]() |
Pocket medicine high-yield board review |
![]() ![]() |
Pocket medicine : the Massachusetts General Hospital handbook of internal medicine |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
A polygenic risk score predicts atrial fibrillation in cardiovascular disease |
![]() |
Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. |
![]() |
Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials |
![]() |
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial |
![]() |
Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease |
![]() |
Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease |
![]() |
The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies |
![]() |
Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial. |
![]() |
Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. |
![]() |
Relation of hyperemic epicardial flow to outcomes among patients with ST-segment elevation myocardial infarction receiving fibrinolytic therapy |
![]() |
Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Cons |
![]() |
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis |
![]() |
Safety of dapagliflozin in a broad population of patients with type 2 diabetes - analyses from the DECLARE - TIMI 58 study |
![]() |
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study |
![]() |
Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial |
![]() |
Sharing Data from Cardiovascular Clinical Trials--A Proposal |
![]() |
Tratamiento de la patología cardiovascular : complemento de "Braunwald, tratado de cardiología" |
![]() ![]() |
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention |
![]() |
Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS). |
![]() |
Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial |
![]() |
内科ポケットレファランス |
![]() ![]() |